Benchmark Reiterates Buy on Agilon Health, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bill Sutherland reiterates a Buy rating on Agilon Health (NYSE:AGL) and maintains a $9 price target.
August 08, 2024 | 4:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst Bill Sutherland reiterates a Buy rating on Agilon Health (NYSE:AGL) and maintains a $9 price target.
The reiteration of a Buy rating and the maintenance of a $9 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100